prolactin breast cancer

Release time ：Dec-23,2024

Prolactin-induced breast cancer is a variant of breast cancer linked to elevated levels of the hormone prolactin. Although this form of breast cancer is uncommon, it underscores the significant role that hormones play in the progression of breast cancer.

Prolactin, a hormone released by the pituitary gland, is primarily responsible for stimulating breast development and lactation. Typically, prolactin levels are low in women who are not pregnant or breastfeeding. However, certain conditions, such as medication use, brain tumors, or endocrine disruptions, can lead to increased prolactin levels. Research indicates that hyperprolactinemia might facilitate the proliferation of mammary epithelial cells by enhancing cell division and suppressing apoptosis, thus elevating the risk of breast cancer.

In cases where prolactin-induced breast cancer is suspected, physicians typically recommend blood tests to measure prolactin levels along with imaging studies like breast ultrasound or mammography to evaluate the patient’s condition. Treatment options may encompass pharmacological interventions to lower prolactin levels, surgical removal of the tumor, and a combination of radiotherapy or chemotherapy. It is crucial for patients to adhere to the prescribed treatment regimen and to engage in regular follow-ups to track any changes in their condition.